This project aims to explore how existing drugs with significant therapeutic potential but notable side effects could be improved via targeted delivery using nanobodies or monoclonal antibodies. A specific focus will be placed on drugs already on the market, where bioavailability issues or off-target toxicity are limiting their effectiveness. The project will involve a literature-based review and/or modelling of delivery strategies (e.g. antibody-drug conjugates, nanobody carriers, PEGylation), with the goal of proposing novel optimisations that increase therapeutic precision.

For pharmaceutical companies, optimising delivery means better efficacy and lower development costs for next-generation versions of existing assets. It supports lifecycle management, increases patient compliance, and may open up new indications. The project also offers insights that could accelerate reformulation strategies.

I’m fascinated by the combination of molecular engineering and clinical application. The idea of taking a molecule that already works and making it smarter, safer, and more patient-friendly captures my interest and aligns closely with my future goals in Pharmatechnology.

I bring a strong academic foundation in immunology, bioinformatics, biochemistry, and drug development, alongside a natural curiosity and a detail-oriented mindset. I work with structure and clarity, love challenging questions, and thrive when combining science with practical problem-solving. You’ll get someone who shows up prepared, takes initiative, and genuinely wants to contribute.